An interventional study of Teleconsultation assisted by a physiotherapist or nurse in ALS and Charcot Disease, sponsored by AGIR à Dom. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by AGIR à Dom · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.
Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 68th largest by enrollment of the 103 interventional ones that give a count, is one of 11 that started in 2023, is one of 47 with no phase, and was the 100th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Prilenia · Sites in France, United States, Belgium and 10 more countries
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+ · Healthy volunteers
Zydus Therapeutics Inc. · Sites in France, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 27 · Phase 3 27
First in 1996; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is close to the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 83 across the 103 interventional studies, 138 across the 29 observational. Of the 79 that completed or were terminated, 21 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 132 have an industry lead sponsor. The 10 most frequent:
AGIR à Dom is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
AGIR à Dom has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT06249412Groupe Hospitalier du HavreThe Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients | 2026-12-01 |
| NCT05632757Assistance Publique Hopitaux De MarseilleAnticipated Patient and Caregiver Burden | 2026-12-22 |
| NCT05819931University Hospital, ToulouseBreathing With Amyotrophic Lateral Sclerosis | 2026-12-31 |
| NCT07091799University Hospital, BordeauxInterest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Satisfaction of patients with amyotrophic lateral sclerosis under non-invasive ventilation regarding home assisted teleconsultation
Amyotrophic Lateral Sclerosis (ALS) is a progressive and rapidly progressing neurodegenerative disease. Depending on the degree of muscle damage, patients may suffer from reduced mobility, difficulty swallowing, speech difficulties and finally respiratory weakness. Death occurs within an average of 2-3 years and is usually due to respiratory failure. Currently there is no cure for ALS, so palliative care and symptomatic treatments are essential for the management of these patients.
The gold standard treatment for respiratory impairment is non-invasive ventilation (NIV). The aim of this mask ventilation is to improve gas exchange by compensating for the weakness of the respiratory muscles.
The progressive nature of ALS requires regular assessment of the patient's clinical condition and evaluation of NIV parameters. Regular medical appointments are therefore essential to ensure optimal ventilation and close surveillance of the patient. A day hospitalization or a consultation is organized every 3 or 4 months. These visits can cause significant fatigue, not only because of the difficulty patients have to move around but also because of the time spent waiting in hospital.
ALS is characterised by its severity and it requires our society to think about and implement new ways of managing the disease. Thus, e-health innovations could be an interesting potential in the remote follow-up of these patients, to reduce the burden of hospital consultations.
The hypothesis is that the patient will be more satisfied with a home assisted teleconsultation follow-up, while keeping the same quality of non-invasive nocturnal ventilatory assistance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.
Other: Teleconsultation assisted by a physiotherapist or nurse
Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).
A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions. This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.
Satisfaction of ALS patients followed by teleconsultation at home
Evolution of the overall satisfaction score obtained from the Client Satisfaction Questionnaire CSQ-8, with 8 items, score 8-32. The higher the score, the more satisfied the patient is.
Time frame: Between the initial visit and the 3-month visit
Evolution of the patient's physical functions
Change in ALS-FRS-R (Amyotrophic lateral sclerosis functional rating scale revised) questionnaire score, score 0-48. The higher the score, the better the patient's physical function.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean nocturnal oxygen saturation (SpO2, %) measured by oximetry
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) below 90% SpO2, measured by oximetry
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean PtCO2 (in mmHg), measured by capnography
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from clinical parameters measured by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire, score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from mean PtCO2 (in mmHg), measured by capnography
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) below 90% SpO2, measured by oximetry
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from mean nocturnal oxygen saturation (SpO2,%) measured by oximetry
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Patient satisfaction with teleconsultation itself (use and patient/doctor interaction)
Evaluation of the score of the Visit Satisfaction Questionnaire (VSQ-VF) score 0-100. The higher the score, the more satisfied the patient is.
Time frame: After each teleconsultation (3-month visit and 6-month visit)
The evolution of satisfaction between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the variation in the score of the visit satisfaction questionnaire, assessed by the VSQ-VF questionnaire, score 0-100. The higher the score, the more satisfied the patient is.
Time frame: Between the 3-month visit, and the 6-months visit
Physician satisfaction with teleconsultation
Evaluation made by Visual Analogue Scale (VAS) from 0 to 10 cm. The higher the score, the more satisfied the physician is.
Time frame: After each teleconsultation (3-month visit and 6-month visit)
Caregivers' satisfaction with the care of the relative
Change in caregiver satisfaction measured with client satisfaction questionnaire score (CSQ-8 modified) with 8 items, score 8-32. The higher the score, the more satisfied the caregivers' is.
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
The feasibility of home teleconsultation for ALS patients
Number of failed teleconsultations requiring rescheduling
Time frame: Between the initial visit, the 3-month visit, and the 6-months visit
Retention of follow-up modality
Number of patients who changed follow-up modality, assessed by the number of face-to-face follow-up
Time frame: At 6 months
Ran from Jan 2023 to primary completion in Dec 2024, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
AGIR à Dom